Tonix Pharmaceuticals (TNXP) Receiving Somewhat Positive Media Coverage, Analysis Finds

Media headlines about Tonix Pharmaceuticals (NASDAQ:TNXP) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Tonix Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.5986328830572 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Tonix Pharmaceuticals (NASDAQ TNXP) traded up $0.03 during midday trading on Friday, reaching $3.66. The company had a trading volume of 26,500 shares, compared to its average volume of 57,975. Tonix Pharmaceuticals has a 12 month low of $2.85 and a 12 month high of $9.40. The firm has a market cap of $28.31, a PE ratio of -0.77 and a beta of 2.92.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 7th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.02). research analysts forecast that Tonix Pharmaceuticals will post -3.23 EPS for the current fiscal year.

Several equities analysts have recently issued reports on TNXP shares. ValuEngine cut Tonix Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Monday, October 2nd. Aegis reaffirmed a “buy” rating on shares of Tonix Pharmaceuticals in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $8.33.

In other news, Director Ernest Mario sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $3.57, for a total value of $35,700.00. Following the completion of the sale, the director now directly owns 10,000 shares in the company, valued at $35,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 48,934 shares of company stock valued at $172,496 over the last 90 days. Company insiders own 4.00% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Insider Buying and Selling by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply